Octreotide
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypothalamic Obesity
Conditions
Hypothalamic Obesity
Trial Timeline
Feb 1, 2005 → —
NCT ID
NCT00171613About Octreotide
Octreotide is a approved stage product being developed by Novartis for Hypothalamic Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT00171613. Target conditions include Hypothalamic Obesity.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00332969 | Phase 2 | Completed |
| NCT00171613 | Approved | Completed |
| NCT00171886 | Approved | Completed |
| NCT00241020 | Phase 3 | Completed |
| NCT00521300 | Approved | Completed |
Competing Products
7 competing products in Hypothalamic Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mibavademab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part C: RM-718 + Part D: RM-718 | Rhythm Pharmaceuticals | Phase 1/2 | 38 |
| Setmelanotide + Placebo | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide + Placebo | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide | Rhythm Pharmaceuticals | Phase 2 | 49 |
| Bivamelagon | Rhythm Pharmaceuticals | Phase 2 | 49 |
| LB54640 + Placebo | Rhythm Pharmaceuticals | Phase 2 | 49 |